Freelance Pharmaceutical And Biotech Writer
Nick Paul Taylor is a Freelance Pharmaceutical and Biotech Writer. He specializes in topics related to medicine and healthcare, with a focus on biotech, FDA regulations, AI, and market trends, as well as the impact of the coronavirus. Nick's work has been featured in prominent publications such as Healthcare Dive, BioPharma Dive, and Fierce Pharma.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Nick Paul Taylor's articles are focused on the healthcare and pharmaceutical industry, particularly highlighting data-driven content. His coverage centers around medical technology, pharmaceutical companies, clinical trials, drug development, and biotechnology.
Given his focus on citing data and press releases, Nick is likely to be interested in pitches that provide newsworthy statistics or insights from credible sources within the healthcare and pharmaceutical sectors. He may also respond well to pitches related to government announcements impacting these industries.
As he does not have a specific geographic focus mentioned but covers global pharmaceutical news extensively, consider providing international perspectives or insights when reaching out for potential collaboration.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Aileron Therapeutics pulled a hard pivot in 2023, merging with Lung Therapeutics to gain a new pipeline and investor base.
By: Nick Paul Taylor
A report found China limits EU-based device manufacturers’ access to its market through policies that favor local suppliers in an “unfair and discriminatory way.”
By: Nick Paul Taylor
GlobalData analysts are predicting an Alzheimer's disease market boom, tipping its value across major regions to increase eightfold in a decade as therapies address unmet medical need.
By: Nick Paul Taylor
The data suggest the high dose nearly closes the efficacy gap with Zepbound.
By: Nick Paul Taylor
The new director of the FDA’s device center contrasted a European rule with the U.S.’s lack of mandatory reporting requirements for potential device shortages.
Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks in 2024.
By: Nick Paul Taylor
Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an early look at how receptive public investors could be to biotech listings in 2025.
By: Nick Paul Taylor
Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure the rights to promote and sell the PD-1 inhibitor in its home region.
By: Nick Paul Taylor
A trio of Chinese biotechs have filed to go public, setting the stage for offerings that could fill the coffers of companies that have big deals with Bristol Myers Squibb and Takeda.
By: Nick Paul Taylor
Xeris Pharmaceuticals has teamed up with the American Diabetes Association (ADA) to raise awareness of the importance of prescribing glucagon, positioning
(833) 317-6278 
